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As surgeons who care for patients with breast cancer, the possibility of a cancer diag-
nosis being related to a hereditary predisposition is always a consideration. Not only are 
we as surgeons always trying to identify these patients and families but also we are often 
asked about a potential hereditary component by the patients and their family members. 
It is therefore critical that we accurately assess patients to determine who may benefit 
from genetic testing. Importantly, the potential benefit for identifying a hereditary breast 
cancer extends beyond the patient to other family members and the risk may not be only 
for the development of breast cancers, but for other cancers as well. This review was 
written from the perspective of a surgeon with additional training in cancer genetics in an 
effort to provide a unique perspective on the issue and feel that a review of some of the 
more practical considerations is important.
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iNTRODUCTiON
As surgeons who care for patients with breast cancer, the possibility of a cancer diagnosis being 
related to a hereditary predisposition is always a consideration. Not only are we as surgeons always 
trying to identify these patients and families but also we are often asked about a potential hereditary 
component by the patients and their family members. It is therefore critical that we accurately assess 
patients to determine who may benefit from genetic testing. Importantly, the potential benefit for 
identifying a hereditary breast cancer extends beyond the patient to other family members and the 
risk may not be only for the development of breast cancers, but for other cancers as well. This review 
was written from the perspective of a surgeon with additional training in cancer genetics in an effort 
to provide a unique perspective on the issue and feel that a review of some of the more practical 
considerations is important.
Hereditary cases of breast cancer have long been recognized to occur, but the ability to test for a 
marker of risk is a relatively recent occurrence. The first study demonstrating evidence of an autoso-
mal dominant pattern of inheritance for breast cancer was published in 1988 (1). Soon after, linkage 
to a gene on chromosome 17 was established, and the BRCA1 gene was identified (2, 3). Shortly 
after that, a second breast cancer susceptibility gene, BRCA2, was identified (4). By 1996, the first 
molecular test for hereditary breast and ovarian cancer was introduced by Myriad Genetics. This test 
was initially performed on a blood sample and consisted of sequencing the BRCA1 and 2 genes. Over 
the years, the test has improved to detect deletions and rearrangements that may have been missed 
with standard sequencing and can now be performed on either a blood or buccal sample. Additional 
genes have also been associated with increased risk for breast cancer (Figure 1), and new technology, 
referred to as next generation sequencing, has allowed for testing for mutations in numerous genes 
with a single blood sample.
FiGURe 1 | Genes associated with elevated breast cancer risk (figure 
courtesy of Alexandra Suttman, BA, genetic counseling student, The 
Ohio State University).
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RiSK ASSeSSMeNT
There are many instances where a patient’s risk can be assessed. 
Certainly, when assessing a newly diagnosed breast cancer, the 
age of onset of the cancer, specific biomarkers, and family history 
assessment may indicate concern for hereditary risk. Identifying 
unaffected individuals with hereditary risk is also of critical 
importance, whether they are identified due to a known genetic 
mutation in a family member or due to suggestive family history. 
The US Preventive Services Task Force has published recom-
mendations regarding risk assessment, genetic counseling, and 
genetic testing for BRCA-related cancers in women (5).
It is well established that when evaluating a new patient, a fam-
ily history is obtained, but often many of the important features 
necessary to identify a family at hereditary risk are not assessed. 
When assessing a family for hereditary risk, a complete history 
should be obtained to include three generations and note all 
cancer diagnoses and ages of diagnosis. The comprehensiveness 
of family cancer history assessments and cancer risk assessment 
in primary care has been investigated by Murff and colleagues 
(6, 7). In the first report, a retrospective chart review, the authors 
reviewed the charts of 995 new patent visits to 28 primary care 
providers to evaluate the completeness of family history of colon 
or breast cancer. Of the entire sample, 7% contained no documen-
tation of any family history information. Cancer family history 
information was only collected on 68% of the patients, and spe-
cific information regarding the affected individual and diagnosis 
was only present in 61% of the records. Age at diagnosis in first 
degree relatives was documented in 38% of breast cancers and 
27% of ovarian cancers. Only 17% of those who met criteria for 
early onset breast cancer were identified and referred for genetic 
testing services (6). In a later study, these investigators compared 
family history information collected through self-completed 
surveys to the documentation in the chart. Once again, age was 
often missing on chart review (recorded in 40%) but was much 
more commonly reported in the survey (81%) (7). The utilization 
of these surveys, the authors concluded, may address some of 
the limitations to obtaining an appropriate history in a primary 
care office, including limited provider time, competing clinical 
diagnoses, provider–patient communication issues, and lack of 
both provider and patient education regarding the importance of 
family cancer history on cancer risk assessment.
In an elegant study by Burke and colleagues, primary care 
physicians were presented three different unannounced stand-
ardized patient case scenarios (moderate risk, high-risk maternal 
and high-risk paternal, and all audiotaped), and at the conclusion, 
were asked to complete a brief detection questionnaire. Similar 
deficits in completeness of family history were identified, and 
again age of onset was often not assessed. Physicians did least 
well identifying risk due to paternal family history and some 
physicians’ comments ascribed less significance to the paternal 
family history of breast cancer than the maternal family history. 
Many did elicit or recognize the important contribution of ovar-
ian cancer to hereditary breast cancer risk assessment (8). This 
study demonstrates a lack of understanding of the autosomal 
dominant inheritance pattern of hereditary breast and ovarian 
cancer syndrome and the importance of paternal family history 
and ovarian cancer history.
Even in specialized clinics, in more contemporary settings, 
identification of high-risk patients has been difficult. Ow and 
colleagues retrospectively reviewed over 6000 pedigrees at their 
center in Singapore over a 10-year period to identify those with 
over a 10% risk of having a BRCA mutation. Of the 615 identified, 
506 had medical records available for review, and they found that a 
good family history spanning three generations was documented 
in only 54% and was taken less frequently than smoking and 
drinking history. On univariate analysis, they found that taking 
a good family history and young age of onset of cancer increased 
the likelihood of physician suspicion (9).
Patient issues also play a role in failure to identify patients at 
risk for hereditary cancer. Even when the appropriate questions 
are asked, the quality of family history data is dependent on the 
accuracy of patient reporting. In a study of over 43,000 women 
presenting for screening mammogram, Ozzane and colleagues 
reviewed the reported numbers of breast, colon, prostate, lung, 
and ovarian cancers and compared those reported in the maternal 
and paternal relatives and in first- and second-generation rela-
tives. Self-reported family histories were significantly influenced 
by bloodline and degree of relative affected, with lower reporting 
of all cancers with the exception of prostate cancer in the paternal 
lineage and in second degree relatives (10).
COUNSeLiNG AND TeSTiNG iSSUeS
Once an accurate personal and family history has been obtained, 
the issue of genetic testing can be explored, but when should the 
test be ordered, who should order the test and how should results 
be communicated? Individuals at risk for hereditary cancer can 
be identified at multiple different times. They may be identified 
after diagnosis and definitive treatment of breast cancer, after 
diagnosis but before definitive treatment, and when unaffected. 
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Each scenario presents its own set of challenges and different 
approaches to the patients with respect to counseling, testing, and 
risk management are required (11). Since the testing is expensive, 
insurance coverage can be a concern. Most insurance companies 
have established criteria for coverage of genetic testing based on 
the National Comprehensive Cancer Network’s guidelines (12). 
Some of the newer panel tests are not covered by some insurers.
For unaffected individuals at risk, positive results will help 
to quantify risk. Generally, options for management of risk 
include surveillance with regular mammography and clinical 
examination and in some cases, MRI, chemoprevention, and risk-
reducing surgery. Negative genetic test results, however, may not 
completely eliminate risk. Without testing an affected individual, 
it is not clear if a negative result indicates population risk, because 
the mutation in the family was not inherited, or persistent risk, 
because the genes tested for are not responsible for the cancers in 
the family. For those with a new diagnosis who have not yet had 
definitive surgery, genetic testing results may influence surgical 
decisions. For example, if a patient tests positive for a mutation 
in one of the BRCA genes, she may choose to have bilateral mas-
tectomy due to increased risk of contralateral cancer compared 
to non-mutation carriers. Identification of other mutations less 
well described than BRCA1 and 2 may not influence surgical 
decisions, since less information regarding contralateral cancer 
risks is known. The timing necessary for counseling and testing in 
the perioperative period may lead to delays in care or may cause 
additional anxiety if results are not obtained prior to surgery. 
In our institution, surgical decision-making cases are generally 
seen within 1 week, but extent of testing will impact timing of 
results availability. If only BRCA testing is performed, results are 
generally available within 1 week, but if a panel of genes is tested, 
results can take 4–6 weeks.
Regardless of the timing of testing, the growing complexity 
of genetic testing options, including testing for panels of genes 
for which less information is available, make pre-test and post-
test counseling important components of the process (12). 
Pre-test counseling should include an assessment of risk and a 
discussion of the differential diagnosis along with education of 
the inheritance patterns, penetrance, and variable expressivity. 
Pre-test counseling in general is associated with improvement in 
cancer-specific knowledge and minimal adverse psychological 
consequences (13). Direct to consumer testing has emerged as 
another option for patients. This refers to genetic testing mar-
keted directly to consumers via a variety of methods, including 
television, print ads, and the internet and does not necessarily 
involve a physician or insurance company. There is little to no 
counseling performed prior to testing. The results are shared 
directly with the consumer. In some cases, a genetics professional 
may be involved in explanation of the results. There are significant 
risks and limitations to these tests, as consumers may be misled by 
unproven tests and without guidance from a physician or coun-
selor, they may make important health care decisions based on 
inaccurate or incomplete information. In spite of these concerns 
and limitations, available published data suggest that clear benefit 
was provided to participants without serious emotional distress 
or inappropriate actions (14). Women with breast cancer even 
preferred testing without prior counseling and did not experience 
increased distress (15). It is important to note, however, that the 
current body of literature regarding direct to consumer testing 
predated panel testing, which certainly does complicate the 
interpretation of results.
When pre-test counseling is performed, it is generally per-
formed by a genetic counselor, medical geneticist, surgical or 
medical oncologist, or other health professional with expertise 
and experience in cancer genetics. Some insurance companies, 
including Cigna and United Health Care, require that counseling 
be provided by a certified genetic counselor prior to testing. The 
American Society of Clinical Oncology recently published a 
policy statement update on genetic testing for cancer suscepti-
bility. The recognition and management of individuals with an 
inherited susceptibility to cancer is considered a core element 
of oncology care, and as such, continued education of oncolo-
gists and other health professionals in the area of cancer risk 
assessment and management of individuals with an inherited 
predisposition to cancer is recommended (16). The key factor is 
expertise and experience in cancer genetics. Educational courses 
and self-teaching tools are available through City of Hope and 
ASCO.
Cragun and colleagues assessed the potential differences in 
genetic counseling and testing services between board-certified 
genetic health-care providers and non-genetic health care 
providers by surveying patients who had undergone testing. 
They evaluated patient recall and content of precounseling for 
hereditary breast and ovarian cancer and whether BRCA1 and 2 
gene sequencing was performed when less expensive single site 
or Ashkenazi Jewish founder mutation testing may have been suf-
ficient. They found that genetic health-care provider involvement 
was associated with not only adherence to nationally recom-
mended genetic counseling practices but could also reduce cost 
of testing (17). Vadaparampil and colleagues examined whether 
non-genetics professionals in Florida performed guideline-based 
patient intake and informed consent before genetic testing. They 
surveyed 386 non-genetics providers offering BRCA testing in 
the state of Florida. Of the 81 respondents to the survey, few 
constructed three-generation pedigrees, discussed alternative 
hereditary cancer syndromes or discussed the meaning of a vari-
ant result. Approximately half reported sometimes scheduling a 
separate session for pre-test counseling, discussing family impli-
cations of testing, benefits and limitations of risk management 
options, and discussion of the potential psychological impact and 
insurance-related issues. This lack of adherence to established 
guidelines may result in harm to patients and their families, 
including ordering the wrong test, negative emotional effects, 
receiving incorrect medical management guidelines, and mis-
interpretation of results, leading to wasted health care resources 
and unnecessary preventive surgeries. In instances where the 
non-genetics provider cannot provide these services, referral to a 
genetics professional is encouraged (18), but as noted above, non-
geneticists who learn the tools can appropriately counsel patients.
Testing of affected individuals who have already been treated 
for their cancer is routinely performed and is historically the way 
testing was initiated in families with hereditary risk. With the 
growing public knowledge regarding hereditary forms of breast 
cancer, newly diagnosed patients who have not yet had treatment 
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often wonder about their hereditary risk and contemplate test-
ing. Testing could be considered once the primary tumor has 
been treated, but is often being considered prior to definitive 
therapy. Concern exists regarding the appropriateness of genetic 
counseling and testing in newly diagnosed patients who have 
not yet had definitive surgery. This testing may have important 
implications for surgical decision making, including consid-
eration of contralateral prophylactic mastectomy or the use of 
certain adjuvant systemic therapies, such as PARP inhibitors and 
platinum compounds (19, 20), but the priority of care should 
be appropriate treatment of the malignancy already diagnosed 
rather than one that may or may not occur in the future. In a 
study evaluating those with breast cancer who had pre-test coun-
seling, cancer-related knowledge was increased for all. For those 
counseled before definitive surgery, distress was lowered, but 
increased decisional conflict related to the decision for genetic 
testing was noted, although this was not statistically significant; 
for those counseled after definitive surgery, informed decision 
making was improved (21). In another study, newly diagnosed 
breast cancer patients were randomized to a group offered rapid 
genetic counseling and testing and a usual care control group. 
Two hundred sixty-five patients were recruited over a 2-year 
period, 178 of whom were in the intervention group. Genetic 
counseling was performed in 177, of whom 71 (40%) had rapid 
genetic testing and 59 (33%) received results prior to surgery. In 
this study, those who had rapid genetic counseling and testing did 
not have any measurable adverse psychosocial effects, including 
cancer worries, cancer-specific distress, anxiety and depression, 
cancer-specific health-related quality of life, and satisfaction with 
decision making and decisional conflict (22).
For unaffected women with a strong family history of breast 
cancer, genetic counseling is also valuable. A Cochrane review of 
genetic risk assessment for individuals at risk of familial breast 
cancer was published in 2012, and although this review found 
favorable outcomes for patients after risk assessment, there were 
too few papers to make any significant conclusions about how 
best to deliver services (23). Fear of developing breast cancer 
is often experienced by women with a strong family history of 
breast cancer, and many of these women may consider preventive 
surgery based on their perceived risks. Genetic counseling may 
help to more accurately quantify risk to allow women to make a 
more informed choice regarding screening and prevention, even 
if testing is not ultimately performed. In one study, a total of 83 
women were referred for genetics evaluation based on perceived 
breast cancer risk. Of these, 31 were considering risk-reducing 
surgery, 23 of whom were thought to have an elevated risk of hav-
ing a BRCA mutation. Ten women were tested, and a mutation 
was discovered in five. After counseling and testing, only 18 (58%) 
proceeded with risk-reducing surgery, highlighting the lack of 
clear understanding of risk in the medical and lay community 
(24). Both carriers and non-carriers of mutations derive benefit 
from the testing process, although women with a positive result 
may have a sustained increased in breast cancer distress following 
results disclosure without other adverse psychological outcomes 
(25). Fear exists, particularly among unaffected individuals, that 
genetic test results will be somehow used against them. Despite 
the passage of the Genetic Information Non-discrimination act 
(GINA), patient and provider awareness of legal protections for 
genetic testing remains low, leading to continued fears of genetic 
discrimination (26). GINA prohibits employers and health insur-
ance companies from discriminating against an individual based 
on his or her genetic information. Specifically, genetic test results 
cannot be used to affect premium rates, deny coverage or make 
employment determinations. GINA does not, however, protect 
against life insurance discrimination.
Once counseling is completed, the genetic testing options 
should be considered, and risks, benefits, and limitations of the 
testing options discussed. Once this is complete, testing can be 
ordered and a plan should be made for disclosure of results. The 
options for testing have expanded in the last 2 years for two major 
reasons. The patent held by Myriad Genetics was overturned, 
enabling other laboratories to offer BRCA testing and newer 
technology (next generation sequencing) became available, 
allowing more extensive testing from a single blood sample. 
Testing options currently include testing only for BRCA1 and 2 
mutations, testing for a panel of high-risk breast cancer genes, 
including BRCA1 and 2, and more extensive panels including 
moderate risk genes and limited evidence genes. Testing with a 
panel seems most appropriate when there is concern for more 
than one hereditary condition. For example, in a family with 
early onset breast cancer (under the age of 35), ovarian cancer, 
and early onset colon cancer, panel testing would be ideal, since 
potential responsible genetic syndromes include Hereditary 
Breast and Ovarian Cancer Syndrome, Li Fraumeni syndrome, 
and Lynch Syndrome.
Results interpretation is not always straightforward. For the 
high-risk genes, cancer risks and management options are fairly 
well established. The moderate risk genes have generally been 
seen more frequently in individuals with a strong family history 
of breast cancer in whom BRCA testing was negative, but the 
exact cancer risks and management options are not clear. It is 
also not clear whether these gene mutations are sufficient to 
explain the family history themselves or if, more likely, other 
modifier genes impact the likelihood of cancer development. It 
is therefore still debated among genetic professionals whether 
or not predictive testing of unaffected individuals is appropriate. 
In addition, a number of different testing results are possible. It 
is possible that a deleterious mutation in a well-described gene 
could be identified. This would mean that the affected individual 
is at increased risk for the development of cancer and that family 
members are at risk. The result could be negative for a deleteri-
ous mutation, but the implications of this negative result will 
vary based on the individual tested and the family history. An 
unaffected individual who tests negative for a known mutation 
in a family can be reassured by these negative results, as their 
cancer risks will be more closely aligned with population risk. 
Results can also be uninformative. An affected family member 
who tests negative for only BRCA1 or BRCA2 may have another 
hereditary condition not tested for. In an unaffected person with 
strong family history and no prior testing in the family, risk may 
still be elevated based on family history, but could be reduced 
to population if another family member was found to carry a 
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mutation. An even more potentially confusing result is a variant 
of uncertain significance, or VUS. These variants are usually 
relatively minor changes in the genetic code for which insuf-
ficient evidence exists to determine their relevance. Decisions 
about risk management should not be based on these results, 
but rather on the family history. These unclear results may be 
eventually reclassified by tracking their presence with those 
affected with cancer in the family or with further functional 
studies, but this process can take years. In addition, since the 
contribution of these changes to cancer risk are not clear, predic-
tive testing is not recommended for other at risk individuals. 
This is an area of potential harm to patients, since misinterpreta-
tion of these results could lead to unnecessary risk reduction 
strategies, including unnecessary surgeries. Patients who are 
found to have a VUS are more likely to have residual cancer 
distress than patients who have a negative but uninformative 
result, but genetic counseling has been shown to help with their 
understanding of their and their family’s risk, helped them make 
medical decisions to assist in lowering their risk, and decreased 
worry (27).
ReSULTS DiSCLOSURe AND POST-TeST 
COUNSeLiNG
Post-test counseling should include an explanation of results, 
options for managing risk, as well as discussion of the impli-
cations for other family members. One of the distinguishing 
features of genetic medicine is that the discovery of a hereditary 
predisposition to cancer or other disease has implications not 
only for the individual tested, but also for their family members. 
The transmission of this information is generally accomplished 
by communication between the patient and each of his or her 
relatives. Although it is well recognized that family history 
impacts risk, there are barriers to patients disclosing their 
genetic testing results to their families. These include difficult 
or distant family relationships, lack of perceived usefulness, the 
serious nature of the message, and the concern that the mes-
sage will be rejected (28, 29). In a study of 273 women assessed 
4 months after BRCA1/2 result disclosure, demographic, health 
and test-related factors predicted communication of results 
to family members. Female relatives were more likely to be 
informed than males (23% of participants did not inform their 
father and 29% of brothers were not informed). Inconclusive 
results (negative without known familial mutation or variant 
of uncertain significance) were less likely to be conveyed than 
conclusive (positive or true negative) results. Women over 
the age of 40 were less likely to convey results to their parents 
than women under age 40. Age influenced communication to 
children, but most children were told (30). In another study, 
relatives of BRCA1/2 positive individuals were offered cost-free 
and confidential genetic counseling and testing. They were 
then surveyed about disclosure of their genetic testing results. 
Seventy-seven percent of those surveyed disclosed results to all 
at risk relatives. The disclosure of results to first degree relatives 
was higher than to second or third degree relatives. Disclosure 
rates to males and females were similar, but women who 
received the results were more likely to have genetic testing, 
as were individuals from the maternal lineage. Men were more 
likely to express difficulty discussing results and women were 
more likely to experience emotional distress associated with the 
results disclosure (31).
How can we as providers guide patients and facilitate intra-
familial communication? McClellan and colleagues conducted 
an exploratory study to assess resources to support patients and 
health-care providers, specifically addressing intrafamilial com-
munication of cancer risk (32). Resources are provided by health-
care professionals, health service organizations, and patient 
groups, but not all of the materials are always cohesive. Among 
health-care professionals, most of the resources acknowledge the 
importance to family members and may provide information 
regarding consequences to families, but do not often address 
the logistics of message delivery or provide tools or direction to 
aid in message delivery. These resources addressing logistic of 
message delivery and the provision of tools, such as sample let-
ters, are more available through service organizations of patient 
groups. Overall, though, few resources are offered in support of 
intrafamilial communication, and further consideration of these 
complex issues is necessary to aid patients in sharing this complex 
information with their family members.
A randomized clinical trial conducted in the Netherlands 
assessed the use of the Informing Relatives Inventory, a battery of 
instruments measuring knowledge, motivation, and self-efficacy 
regarding disclosure of hereditary information to at-risk relatives, 
and found that it improved insight into patients’ barriers regard-
ing result disclosure (33). Further research is needed to assess 
these barriers more completely, however, and provide insight into 
ways to assure that results disclosure occurs to all family members 
who might benefit from the information.
Ensuring that family members are made aware of the risk is 
not always easy, as patients are not legally required to disclose 
medical information to their relatives. In addition, the Health 
Insurance Portability and Accountability Act (HIPAA) prohibits 
health-care professionals from disclosing a patient’s information 
to third parties, including family members. When communica-
tion between patient and relatives fails, what is the responsibility 
of the provider? In some instances, the law mandates release of 
medical information to third parties (transmissible diseases, 
child abuse, domestic violence, or conditions that constitute a 
danger to public safety), but to date, genetic testing results have 
not been considered exempt from privacy laws. Even if not sub-
ject to HIPAA laws, disclosing genetic test results to all family 
members of an affected individual places an unrealistic burden 
on the practitioner. So while it is acknowledged that health-care 
providers have a duty to inform patients about the implications of 
test results for the family and should encourage the dissemination 
of this information, it is currently beyond the scope of practice for 
most providers. Certain circumstances may provide additional 
challenges. For example, what if the individual tested is deceased? 
What about children relinquished to adoption? Further discus-
sion is necessary to determine the best way to assure that those 
who benefit from learning the family’s results can obtain the 
information necessary to address their own surveillance needs.
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FUTURe DiReCTiONS
There has been tremendous growth in the ability to test for 
potential hereditary causes of cancer, but the testing to date has 
largely been guided by family history. As we continue to person-
alize cancer care, BRCA testing or testing for other genes, will 
likely be performed for all patients newly diagnosed with breast 
cancer. There are already some therapeutic implications. Poly 
ADP-ribose polymerases (PARPs) are important components of 
the base excision repair pathway for single strand DNA breaks. 
PARP inhibitors, therefore, block this mechanism of DNA repair. 
These agents have shown the most promise in patients with 
breast or ovarian cancer who have germ line BRCA mutation or 
non-mutational functional defects in BRCA proteins (34, 35). 
Along similar lines, early data suggest that BRCA1 mutations 
result in increased sensitivity to DNA damaging chemotherapy, 
including platinum agents, and relative resistance to microtubule 
agents, such as taxanes (36–38). If additional data support the 
importance of BRCA mutation status to determine systemic 
therapy, this testing may be routinely performed at diagnosis. In 
the future, it seems likely that at least some genetic testing will 
be performed in all patients newly diagnosed with breast cancer.
Some argue that waiting until the family meets criteria for 
genetic testing is too late to identify a mutation in the family. 
The ideal time to identify risk is prior to a cancer diagnosis. A 
study published by Manchanda and colleagues evaluated cost-
effectiveness of populations screening for BRCA mutations in 
Ashkenzi Jewish women compared with family history-based 
testing and found that this was highly cost-effective for women 
of Ashkenazi Jewish ancestry 30 years and older (39). Of course, 
testing in this specific population consists of testing for the three 
common mutations that cause 95% of cases of Hereditary Breast 
and Ovarian Cancer in Ashkenazi Jewish individuals. Also, the 
carrier frequency of mutations is 1/40 as opposed to 1/400–800 
in non-Jewish individuals. At this time, population screening of 
non-Jewish individuals is not really feasible or cost-effective, but 
as the cost of testing continues to decrease, this will likely occur.
Finally, as we learn more about the implications of more 
moderate risk genes, the use of widespread panels will likely also 
increase and will likely also expand to routine testing of women. 
This will allow a better identification of those at risk and will 
likely allow better predictions of cancer risks and allow for earlier 
consideration of screening and preventive options.
In summary, genetic testing for breast cancer susceptibility has 
advanced tremendously, but we are only scratching the surface of 
our understanding of the role heredity plays in carcinogenesis. 
There is no doubt, however, that our knowledge will continue to 
grow allowing us to more accurately provide assessment of risk to 
all individuals, regardless of their family history.
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